Detalhe da pesquisa
1.
Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma.
Blood
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38713888
2.
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Lancet
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38705160
3.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med
; 386(26): 2482-2494, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657079
4.
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.
Blood
; 142(2): 141-145, 2023 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37130017
5.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(2): 139-150, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36642080
6.
Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience.
Br J Haematol
; 201(4): 663-672, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36762710
7.
Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.
Br J Haematol
; 198(1): 73-81, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362096
8.
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Blood
; 135(10): 735-742, 2020 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31945149
9.
Improved survival of Burkitt lymphoma/leukemia patients: observations from Poland, 1999-2020.
Ann Hematol
; 101(5): 1059-1065, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293608
10.
Genetic associations with lymphomas in Polish patients: A pooled-DNA genome-wide association analysis.
Int J Immunogenet
; 49(5): 353-363, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36036752
11.
Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
Chemotherapy
; 67(4): 201-210, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35249035
12.
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
N Engl J Med
; 378(4): 331-344, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29224502
13.
Higher genome variability within metabolism genes associates with recurrent Clostridium difficile infection.
BMC Microbiol
; 21(1): 36, 2021 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-33509087
14.
First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Br J Haematol
; 188(6): 898-906, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31792945
15.
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Blood
; 132(25): 2639-2642, 2018 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30266774
16.
Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective.
BMC Cancer
; 20(1): 1088, 2020 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33172440
17.
Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.
Br J Haematol
; 183(3): 400-410, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30168134
18.
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Br J Haematol
; 180(2): 224-235, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29193019
19.
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Lancet
; 390(10094): 555-566, 2017 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28600132
20.
A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration.
Mod Pathol
; 31(5): 732-743, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29327714